Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR T-Cell Therapy in Refractory Systemic Lupus Erythematosus
NCT07432334Phase 1Recruiting
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in systemic lupus erythematosus (SLE), sponsored by Vinmec Research Institute of Stem Cell and Gene Technology. Primary endpoint: Frequency and Severity of Adverse Events and Serious Adverse Events at Day 360. Started Mar 2026; status: recruiting.
02
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07432334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07432334.